Skip to main content
Michael Rosenblum, MD, Dermatology, San Francisco, CA, UCSF Medical Center

MichaelDavidRosenblumMD

Dermatology San Francisco, CA

Assistant Professor in Residence, Dermatology, UCSF School of Medicine

Are you Dr. Rosenblum?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 30 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

  • Office

    1701 Divisadero St Fl 3
    Ucsf Department Of Dermatology
    San Francisco, CA 94115
    Phone+1 415-353-7800
  • Is this information wrong?

Summary

  • Dr. Michael Rosenblum, MD is a board certified dermatologist in San Francisco, California. He is currently licensed to practice medicine in California. He is affiliated with UCSF Medical Center and is an Assistant Professor in Residence at UCSF School of Medicine.

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Dermatology, 2007 - 2010
  • Aurora Health Care
    Aurora Health CareInternship, Transitional Year, 2006 - 2007
  • Medical College of Wisconsin
    Medical College of WisconsinClass of 2006

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2007 - 2025
  • American Board of Dermatology Dermatology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Fellow (FAAD) American Academy of Dermatology

Publications & Presentations

PubMed

Press Mentions

  • TRexBio Chomps down on $59 Million Series A for Immunobiology
    TRexBio Chomps down on $59 Million Series A for ImmunobiologyJune 22nd, 2021
  • TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the Treatment of Cancer and Inflammatory Diseases
    TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the Treatment of Cancer and Inflammatory DiseasesJune 22nd, 2021
  • New Hair Growth Mechanism Discovered
    New Hair Growth Mechanism DiscoveredJune 1st, 2017
  • Join now to see all

Professional Memberships

Hospital Affiliations